VivoSeq
Other

Stem Cell Transplant

6

Pipeline Programs↗

29

Active Trials↗

10

Companies Involved↗

Stem Cell Transplant is an early-stage landscape with 6 programs across 10 companies. The most active players are Merck & Co., Avyxa, Teva.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

19/100

Mech. Concentration

25/100

Completion Rate

62/100

Attrition Rate

30/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2A

Avyxa

1 program

Phase 2Teva logo

Teva

1 program

Phase 2B

Bellicum Pharmaceuticals

0 programs

PreclinicalK

Kiadis Pharma

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

5 of 6 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

164

clinical trials

Completed80 · 49%
Terminated34 · 21%
Recruiting21 · 13%
Withdrawn16 · 10%
Active, not recruiting6 · 4%
Unknown status3 · 2%
Other4 · 2%

Clinical Trials

Trial Activity

164 trials

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Recruiting·UUniversity of Chicago·Phase 1·NCT02333162·30 enrolled
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
Recruiting·UUniversity Hospital Freiburg·Phase 3·NCT06830421·340 enrolled
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06315309·29 enrolled
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
Recruiting·UUniversity of Rochester·Phase 2·NCT03739502·64 enrolled
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
Recruiting·PPorteus, Matthew, MD·Phase 1·NCT04640987·22 enrolled
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Recruiting·HHenry Ford Health System·Phase 2·NCT03850418·43 enrolled
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
Recruiting·UUniversity of Leeds·Phase 3·NCT03562169·406 enrolled
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Recruiting·IImperial College London·Phase 2·NCT06355583·50 enrolled
Autologous Stem Cell Transplant for Crohn's Disease
Recruiting·—·Phase 2·NCT03219359·50 enrolled
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06265584·56 enrolled
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
Recruiting·—·N/A·NCT04249830·204 enrolled
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Recruiting·MMelbourne Health·Phase 4·NCT03717623·100 enrolled
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
Recruiting·—·Phase 2·NCT04230356·180 enrolled
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT06928662·36 enrolled
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05787574·39 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)